Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
3.870
+0.010 (0.26%)
At close: Aug 13, 2025, 4:00 PM
3.990
+0.120 (3.10%)
After-hours: Aug 13, 2025, 6:07 PM EDT

Company Description

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.

The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.

The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.
Neuronetics logo
Country United States
Founded 2003
IPO Date Jun 28, 2018
Industry Medical Devices
Sector Healthcare
Employees 716
CEO Keith Sullivan

Contact Details

Address:
3222 Phoenixville Pike
Malvern, Pennsylvania 19355
United States
Phone 610 640 4202
Website neurostar.com

Stock Details

Ticker Symbol STIM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001227636
CUSIP Number 64131A105
ISIN Number US64131A1051
SIC Code 3841

Key Executives

Name Position
Stephen J. Furlong M.S. Senior Advisor to the Chief Executive Officer
Keith J. Sullivan President, Chief Executive Officer and Director
W. Andrew Macan J.D. Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Steven E. Pfanstiel C.M.A., M.B.A. Chief Financial Officer
Cory S. Anderson SVice President and Chief Technology Officer
Lisa Metzner-Rosas Senior Vice President and Chief Marketing Officer
Sara Grubbs Senior Vice President and Chief Revenue Officer
William P. Leonard Chief Clinic Officer

Latest SEC Filings

Date Type Title
Aug 12, 2025 SCHEDULE 13D/A Filing
Aug 8, 2025 144 Filing
Aug 8, 2025 144 Filing
Aug 8, 2025 144 Filing
Aug 7, 2025 144 Filing
Aug 6, 2025 424B5 Filing
Aug 5, 2025 10-Q Quarterly Report
Aug 5, 2025 8-K Current Report
Jul 18, 2025 EFFECT Notice of Effectiveness
Jul 15, 2025 8-K Current Report